BR112023016580A2 - Anticorpos anti-tcr delta variáveis 1 - Google Patents
Anticorpos anti-tcr delta variáveis 1Info
- Publication number
- BR112023016580A2 BR112023016580A2 BR112023016580A BR112023016580A BR112023016580A2 BR 112023016580 A2 BR112023016580 A2 BR 112023016580A2 BR 112023016580 A BR112023016580 A BR 112023016580A BR 112023016580 A BR112023016580 A BR 112023016580A BR 112023016580 A2 BR112023016580 A2 BR 112023016580A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- tcr delta
- delta variable
- present
- provides
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
anticorpos anti-tcr delta variáveis 1. a presente invenção fornece anticorpos anti-tcr delta variáveis 1 (anti-vd1) de alta afinidade e fragmentos de anticorpo dos mesmos. a presente invenção também fornece composições e composições farmacêuticas que compreendem tais anticorpos e método para produzir tais anticorpos. a presente invenção também fornece métodos de tratamento e usos médicos que envolvem os anticorpos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2102224.9A GB202102224D0 (en) | 2021-02-17 | 2021-02-17 | Anti-TRC delta variable 1 antibodies |
GBGB2111685.0A GB202111685D0 (en) | 2021-08-14 | 2021-08-14 | Anti-tcr delta variable 1 antibodies |
PCT/EP2022/054004 WO2022175413A1 (en) | 2021-02-17 | 2022-02-17 | Anti-tcr delta variable 1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023016580A2 true BR112023016580A2 (pt) | 2023-11-07 |
Family
ID=80595338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023016580A BR112023016580A2 (pt) | 2021-02-17 | 2022-02-17 | Anticorpos anti-tcr delta variáveis 1 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230028110A1 (pt) |
EP (1) | EP4294527A1 (pt) |
JP (1) | JP2024506682A (pt) |
KR (1) | KR20230160253A (pt) |
AU (1) | AU2022224391A1 (pt) |
BR (1) | BR112023016580A2 (pt) |
CA (1) | CA3207265A1 (pt) |
CO (1) | CO2023011853A2 (pt) |
EC (1) | ECSP23070428A (pt) |
IL (1) | IL305024A (pt) |
TW (2) | TW202246338A (pt) |
WO (2) | WO2022175413A1 (pt) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
EA201890013A1 (ru) | 2015-06-09 | 2018-07-31 | Лимфакт - Лимфоцит Активэйшн Текнолоджис, С.А. | Способы получения tcr гамма дельтат-клеток |
CN108473958A (zh) | 2015-10-30 | 2018-08-31 | 癌症研究技术有限公司 | 非造血组织驻留γδT细胞的扩增及这些细胞的用途 |
WO2017197347A1 (en) | 2016-05-12 | 2017-11-16 | Adicet Bio, Inc. | METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
US10546518B2 (en) | 2017-05-15 | 2020-01-28 | Google Llc | Near-eye display with extended effective eyebox via eye tracking |
WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
CN113260629A (zh) * | 2018-09-19 | 2021-08-13 | 拉法医疗有限公司 | 用于治疗恶性血液病的新双特异性抗体 |
GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
US20220135694A1 (en) * | 2019-02-01 | 2022-05-05 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
BR112022001416A2 (pt) * | 2019-08-16 | 2022-06-21 | Gammadelta Therapeutics Ltd | Populações de células t gama delta ex vivo |
MX2022002075A (es) | 2019-08-16 | 2022-03-17 | Gammadelta Therapeutics Ltd | Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr. |
-
2022
- 2022-02-17 JP JP2023548885A patent/JP2024506682A/ja active Pending
- 2022-02-17 TW TW111105807A patent/TW202246338A/zh unknown
- 2022-02-17 EP EP22705063.0A patent/EP4294527A1/en active Pending
- 2022-02-17 US US17/674,129 patent/US20230028110A1/en active Pending
- 2022-02-17 CA CA3207265A patent/CA3207265A1/en active Pending
- 2022-02-17 WO PCT/EP2022/054004 patent/WO2022175413A1/en active Application Filing
- 2022-02-17 BR BR112023016580A patent/BR112023016580A2/pt unknown
- 2022-02-17 WO PCT/EP2022/054011 patent/WO2022175414A1/en active Application Filing
- 2022-02-17 IL IL305024A patent/IL305024A/en unknown
- 2022-02-17 KR KR1020237031271A patent/KR20230160253A/ko unknown
- 2022-02-17 TW TW111105808A patent/TW202302639A/zh unknown
- 2022-02-17 AU AU2022224391A patent/AU2022224391A1/en active Pending
-
2023
- 2023-09-07 CO CONC2023/0011853A patent/CO2023011853A2/es unknown
- 2023-09-15 EC ECSENADI202370428A patent/ECSP23070428A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3207265A1 (en) | 2022-08-25 |
CO2023011853A2 (es) | 2023-12-11 |
WO2022175414A9 (en) | 2023-06-15 |
EP4294527A1 (en) | 2023-12-27 |
ECSP23070428A (es) | 2023-10-31 |
TW202302639A (zh) | 2023-01-16 |
WO2022175413A1 (en) | 2022-08-25 |
AU2022224391A1 (en) | 2023-08-24 |
US20230028110A1 (en) | 2023-01-26 |
KR20230160253A (ko) | 2023-11-23 |
WO2022175414A1 (en) | 2022-08-25 |
IL305024A (en) | 2023-10-01 |
WO2022175414A8 (en) | 2023-11-02 |
TW202246338A (zh) | 2022-12-01 |
JP2024506682A (ja) | 2024-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022001460A2 (pt) | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção | |
BR112017026467A2 (pt) | uso de exossomos para o tratamento de doença | |
BR112016030447A2 (pt) | diacorpo biespecífico de fc capaz de ligação imunoespecífica a um epítopo de pd-1 e a um epítopo de lag-3, composição farmacêutica, método para tratamento de câncer, e, método para tratamento de uma doença associada com a presença de um patógeno | |
CL2021000516A1 (es) | Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
CY1126148T1 (el) | Καινοτομος χιμαιρικη πρωτεϊνη ειδικη για τις cd137 και pd-l1 | |
BR112018074838A2 (pt) | anticorpos anti-ige | |
BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
BR112018075434A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. | |
UY39191A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
BR112018072118A2 (pt) | anticorpos de interferona beta e usos dos mesmos | |
BR112021019854A2 (pt) | Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares | |
BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma | |
BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
CO2020001112A2 (es) | Anticuerpo anti-cd147 | |
BR112023016580A2 (pt) | Anticorpos anti-tcr delta variáveis 1 | |
CO2020012638A2 (es) | Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos | |
BR112020027063A2 (pt) | Tratamento de dor de cabeça com uso de anticorpos anti-cgrp | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
BR112022026341A2 (pt) | Anticorpos e métodos para o tratamento de doenças associadas à claudina | |
BR112023002234A2 (pt) | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 | |
BR112022011122A2 (pt) | Epítopos e anticorpos de trpv1 | |
BR112022002236A2 (pt) | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas |